Brokerages Set Anixa Biosciences Inc (NASDAQ:ANIX) PT at $9.00

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $9.00.

Several research firms have recently commented on ANIX. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Friday, December 12th. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds have recently modified their holdings of ANIX. CIBC Bancorp USA Inc. bought a new stake in shares of Anixa Biosciences during the 3rd quarter valued at $51,000. Marshall Wace LLP bought a new position in Anixa Biosciences in the 2nd quarter worth $39,000. NewEdge Advisors LLC purchased a new stake in Anixa Biosciences in the 2nd quarter worth $33,000. Jane Street Group LLC increased its stake in Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock worth $138,000 after buying an additional 11,340 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after acquiring an additional 29,436 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Trading Down 1.2%

Shares of ANIX stock opened at $3.38 on Monday. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $5.46. The stock has a market cap of $111.27 million, a P/E ratio of -9.66 and a beta of 0.49. The company has a 50 day simple moving average of $3.96 and a two-hundred day simple moving average of $3.60.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.